<DOC>
	<DOCNO>NCT02867566</DOCNO>
	<brief_summary>The purpose study compare Efficacy Safety I-CHOP R-CHOP Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients .</brief_summary>
	<brief_title>A Study Comparing Efficacy Safety Between I-CHOP R-CHOP Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Untreated CD20positive DLBCL confirm histopathology cytology . 18 year 70 year ; Male female patient . International Prognostic Index ( IPI ) score 0 2 . Signed informed consent . At least one measurable lesion : nodal tumor mass , 1.5 cm long axis 1.0 cm short axis ; extranodal tumor mass , 1.0 cm long axis . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . More 6 month life expectancy . Participation another interventional clinical trial past 3 month . Known allergic reaction monoclonal antibody rituximab . Contraindication component CHOP regimen . Previous treatment DLBCL , include chemotherapy , immunotherapy , partial radiotherapy lymphoma , surgical treatment ( exclude tumor mass biopsy surgical resection nonlymphoma lesion ) , prior use monoclonal antibody within 3 month . History cytotoxic drug treatment antiCD20 monoclonal antibody treatment disease ( e.g. , rheumatoid arthritis ) . Primary central nervous system ( CNS ) lymphoma , secondary CNS involvement , primary testicular lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>